The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis
Clinical and Experimental Vaccine Research · 2024 · 13 (3) · 184
DOI: 10.7774/cevr.2024.13.3.184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Vaccine Research, 2024. Verfasst von Marzie Mahdizade Ari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) is consistently ranked among the deadliest diseases worldwide, causing millions of deaths annually. Mycobacterium tuberculosis is the causative agent for this infection. Different antibiotics and vaccines have been discussed as potential treatments and prevention. Currently, there is only one licensed vaccine against TB, Bacillus Calmette-Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and can cause complications in immunocompromised individuals. In this review, BCG, the most widely administered vaccine, is discussed, and the newest vaccines available in medicine are discussed. Based on the restrictions that prevent optimal BCG efficacy and the vaccines that are now being tested in various clinical studies, some criteria need to be considered in designing future vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
ORCID-Profile: Marzie Mahdizade Ari, Masoumeh Beig, Mohammad Sholeh, Majid Khoshmirsafa
Zitieren
APA
Ari, M. M., Beig, M., Sholeh, M., & Khoshmirsafa, M. (2024). The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis. Clinical and Experimental Vaccine Research, 13(3), 184. https://doi.org/10.7774/cevr.2024.13.3.184
Vancouver
Ari MM, Beig M, Sholeh M, Khoshmirsafa M. The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis. Clinical and Experimental Vaccine Research. 2024;13(3):184. doi:10.7774/cevr.2024.13.3.184
BibTeX
@article{Ari2024,
author = {Ari, Marzie Mahdizade and Beig, Masoumeh and Sholeh, Mohammad and Khoshmirsafa, Majid},
title = {The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines against Mycobacterium tuberculosis},
journal = {Clinical and Experimental Vaccine Research},
year = {2024},
volume = {13},
number = {3},
pages = {184},
doi = {10.7774/cevr.2024.13.3.184}
}
EUVIMED